A Review of *Swertia chirayita* (Gentianaceae) as a Traditional Medicinal Plant

Vijay Kumar and Johannes Van Staden*

Research Centre for Plant Growth and Development, School of Life Sciences, University of KwaZulu-Natal, Pietermaritzburg, South Africa

*Swertia chirayita* (Gentianaceae), a popular medicinal herb indigenous to the temperate Himalayas is used in traditional medicine to treat numerous ailments such as liver disorders, malaria, and diabetes and are reported to have a wide spectrum of pharmacological properties. Its medicinal usage is well-documented in Indian pharmaceutical codex, the British, and the American pharmacopeias and in different traditional medicine such as the Ayurveda, Unani, Siddha, and other conventional medical systems. This ethnomedicinal herb is known mostly for its bitter taste caused by the presence of different bioactive compounds that are directly associated with human health welfare. The increasing high usage of *Swertia chirayita*, mostly the underground tissues, as well as the illegal overharvesting combined with habitat destruction resulted in a drastic reduction of its populations and has brought this plant to the verge of extinction. The increasing national and international demand for *Swertia chirayita* has led to unscrupulous collection from the wild and adulteration of supplies. The aim of this review is to provide a synthesis of the current state of scientific knowledge on the medicinal uses, phytochemistry, pharmacological activities, safety evaluation as well as the potential role of plant biotechnology in the conservation of *Swertia chirayita* and to highlight its future prospects. Pharmacological data reported in literature suggest that *Swertia chirayita* shows a beneficial effect in the treatment of several ailments. However, there is lack of adequate information on the safety evaluation of the plant. The pharmacological usefulness of *Swertia chirayita* requires the need for conservation-friendly approaches in its utilization. Providing high-quality genetically uniform clones for sustainable use and thereby saving the genetic diversity of this species in nature is important. In this regard, plant biotechnological applications such as micropropagation, synthetic seed production, and hairy root technology can play a significant role in a holistic conservation strategy. In addition to micropropagation, storage of these valuable genetic resources is equally important for germplasm preservation. However, more advanced research is warranted to determine the activities of bioactive compounds in vitro and in vivo, establish their underlying mechanisms of action and commence the process of clinical research.

**Keywords:** biological activity, conservation, medicinal plant, *Swertia chirayita*, traditional medicine
INTRODUCTION

One of the prerequisites for the success of primary health care is the availability and use of suitable drugs. Traditional medicine is still the most affordable and easily accessible source of treatment in the primary healthcare system. Medicinal plants have always been a potential source to cure different diseases, either in the form of traditional preparations or as pure active principles, and they are frequently the only source of medicine for the majority of people in the developing world.

Swertia, a genus in the family Gentianaceae include a large group of annual and perennial herbs, representing approximately 135 species. Swertia species are common ingredients in a number of herbal remedies. In India, 40 species of Swertia are recorded (Clarke, 1885; Kirtikar and Basu, 1984), of which, Swertia chirayita is considered the most important for its medicinal properties. S. chirayita was first described by Roxburgh under the name of Gentiana chirayita in 1814 (Scartezzini and Speroni, 2000). S. chirayita, common name: “Chiretta” (Figure 1) is a critically endangered medicinal herb that grows at high altitudes in the sub-temperate regions of the Himalayas between 1200 and 2100 m altitudes from Kashmir to Bhutan (Bentley and Trimen, 1880; Clarke, 1885) on the slopes of moist shady places (Gaur, 1999; Figure 2). Its widespread uses in traditional medicine have resulted in over-exploitation from the natural habitat and it is now on the verge of extinction in the wild. S. chirayita is also known by an array of names such as Anaryatikta, Bhunimba, Chiratitka, Kairata in Sanskrit, Qasabuzzarirah in Arab and Farsi, Chiaravata in Urdu, Sekhagi in Burma, and Chirrato or Chiraita in Nepal (Joshi and Dhawan, 2005). Some authors have described S. chirayita as an annual (Anon, 1982; Kirtikar and Basu, 1984) and others as a biennial or pluri-annual (Edwards, 1993). This ethnomedicinal herb is known mostly for its bitter taste caused by the presence of different chemical constituents such as amarogentin (most bitter compound isolated till date), swerchin, swertiamarin, and other bioactive compounds that are directly associated with human health welfare (Joshi and Dhawan, 2005). Due to its excessive over-exploitation from the natural habitat, narrow geographic occurrence (Bhat et al., 2013) and unresolved inherent problems of seed viability and seed germination (Badola and Pal, 2002; Joshi and Dhawan, 2005), alternative approaches for propagation and conservation are urgently required to avoid the possible extinction of this important species. Consequently, S. chirayita has been receiving increasing attention from a wide range of researchers as evident from the number of publications appearing in the literature (Chen et al., 2011; Nagalekshmi et al., 2011; Ghosh et al., 2012; Kumar and Chandra, 2013, 2014, 2015; Fan et al., 2014; Kumar et al., 2014; Sharma et al., 2014, 2015; Padhan et al., 2015; Zhou et al., 2015). However, a comprehensive review detailing the documented ethnomedicinal uses, pharmacological properties and safety evaluation carried out on S. chirayita and identifying the existing knowledge gap is lacking. In this review, we document the medicinal uses and phytochemical properties of S. chirayita. Future prospects including the potential conservation approaches to ensure a continuous supply for both local and international expanding markets and safety

Abbreviations: ABTS, 2,2-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid); ACE, Acetone; BA, 6-benzyl adenine; BHA, Butylated hydroxy anisole; BHT, Butylated hydroxytoluene; 2,4-D, 2,4-Dichlorophenoxyacetic acid; DPPH, 2,2-diphenyl-1-picrylhydrazyl; DW, Dry weight; EtOH, Ethanol; EA, Ethyl acetate; FRAP, Ferric Reducing Antioxidant Power; GA₃, Gibberellic acid; HEX, Hexane; IAA, Indole-3-acetic acid; KN, Kinetin; MeOH, Methanol; NAA, Naphthalene Acetic Acid; PE, Petroleum ether.
evaluation on uses of the species for medicinal purposes are highlighted.

**Botanical Description**

*S. chirayita* is an annual/biennial herb 0.6–1.5 m tall. It has an erect, around 2–3 ft long stem, the middle portion is cylindrical, while the upper is quadrangular, with a prominent decurrent line at each angle. Its stem is orange brown or purplish in color with large continuous yellowish pith (Bentley and Trimen, 1880; Joshi and Dhawan, 2005). Leaves are lanceolate, in opposite pairs, no stalks, acuminate, cordate at the base, sessile, five to seven nerved and 4 cm long (Scartezzini and Speroni, 2000). The root is simple, yellowish, somewhat oblique, or geniculate, tapering and short, almost 7–8 cm long and usually half an inch thick (Bentley and Trimen, 1880; Scartezzini and Speroni, 2000). Flowers are small, numerous, tetramerous, large leafy panicles, green-yellow, and tinged with purple and green or white hairs (Scartezzini and Speroni, 2000; Joshi and Dhawan, 2005). The calyx is gamopphyllous with four lobes, corolla-lobes four twisted and superimposed, united at the base where they have pairs of nectaries on each lobe covered with long hairs. Stamens 4, opposite the corolla lobe, at the base of the corolla. Ovary unilocular with ovules laminal placentation parietale; two stigmas. Capsules are egg-shaped, 2-valved with a transparent yellowish pericarp. Seeds are numerous, very small and dark brownish in color (Chandra et al., 2012). Multi-colored corolla and the presence of nectaries support cross-pollination in *S. chirayita*.

**MEDICINAL USES**

*S. chirayita* a traditional Ayurvedic herb is used by different indigenous population groups in multiple ways for several medicinal purposes (Table 1). The whole plant is widely used by local people for the treatment of hepatitis, inflammation, and digestive diseases (Bhatt et al., 2006). The wide range of medicinal uses include the treatment of chronic fever, malaria, anemia, bronchial asthma, hepatotoxic disorders,
TABLE 1 | Ethnobotanical uses of *Swertia chirayita* in traditional medicine.

| Plant part used | Traditional uses | References |
|-----------------|------------------|------------|
| Whole plant     | Used in several traditional and indigenous systems of medicines, such as Ayurveda, Unani, and Siddha | Mukherji, 1953; Kirtikar and Basu, 1984; Joshi and Dhawan, 2005; |
| Whole plant     | Used in British and American pharmacopeias as tinctures and infusions | Joshi and Dhawan, 2005 |
| Root            | Serves as a drug and an effective tonic for general weakness, fever, cough, joint pain, asthma, and the common cold | Kirtikar and Basu, 1984; Joshi and Dhawan, 2005 |
| Whole plant     | For headaches and blood pressure, the leaves and chopped stems are soaked overnight in water. A paste is prepared and filtered with 1 glass of water. The preparation is consumed once a day for 2–3 days | de Rus Jacquet et al., 2014; Malla et al., 2015 |
| Whole plant     | For Tremor fever, whole *S. chirayita* plants are cut into small pieces and boiled in 1/2 L of water until the volume is reduced to less than half glass. The filtered water is stored in a glass bottle and half spoon is given to children once a day for 2 days. For adult, the posology is 1 spoon once in a day for 2 days and varies to three times a day until cured | de Rus Jacquet et al., 2014 |
| Whole plant     | Boiled in water and one cup of decoction is taken orally to cure malaria | Shah et al., 2014 |
| Whole plant     | Paste of the plant is applied to treat skin diseases such as eczema and pimples | Joshi and Dhawan, 2005; Malla et al., 2015 |
| Whole plant     | Liver disorders; stomach disorders like dyspepsia and diarrhea, intestinal worms | Mukherji, 1953; Joshi and Dhawan, 2005 |
| Whole plant     | Hiccups and vomiting, ulcers, gastrointestinal infections, and kidney diseases | Kirtikar and Basu, 1984 |
| Whole plant     | Used in combination with other drugs in cases of scorpion bite | Nandkarni, 1976 |
| Whole plant     | Used in excessive vaginal discharge | Jadhav and Bhutani, 2005 |

Liver disorders, hepatitis, gastritis, constipation, dyspepsia, skin diseases, worms, epilepsy, ulcers, scanty urine, hypertension, melancholia, and certain types of mental disorders, secretion of bile, blood purification, and diabetes (Karan et al., 1999; Banerjee et al., 2000; Rai et al., 2000; Saha et al., 2004; Chen et al., 2011). Recently, *S. chirayita* extracts showed anti-hepatitis B virus (anti-HBV) activities (Zhou et al., 2015). Traditionally, decoctions of this species are used for antihelminthic, hepatoprotective, hypoglycemic, antimalarial, antifungal, antibacterial, cardiostimulant, antifatigue, anti-inflammatory, antiaging, antiarrheal, as protectant of the heart and also help in lowering blood pressure and blood sugar (Schimmer and Mauthner, 1996). Herbal formulations such as Ayush-64, Diabecon, Mensturyl syrup, and Melicon V ointment (Edwin and Chungath, 1988; Mitra et al., 1996) contain *S. chirayita* extract in different concentrations for its antipyretic, hypoglycaemic, antifungal, and antibacterial properties. Furthermore, the curative value of this herb has also been recorded in ancient Ayurveda medicine systems and other conventional medical systems.

The widespread uses of *S. chirayita* in traditional drugs have resulted in considerable chemical analysis of the plant, and active principles which attribute the plant its medicinal properties. *S. chirayita* is also used in British and American pharmacopeias as tinctures and infusions (Joshi and Dhawan, 2005). The whole plant is used in traditional remedies but the root is mentioned to be the most bioactive part (Kirtikar and Basu, 1984).

**PHARMACOLOGICAL ACTIVITY**

The varied ethnobotanical uses of *S. chirayita* have led to the initiation of various pharmacological investigations. Previous research demonstrates that the *S. chirayita* extracts exhibit a wide range of biological activities, such as antibacterial, antifungal, antiviral, anticancer, anti-inflammatory, and others like antidiabetic and antioxidant activities (Verma et al., 2008; Alam et al., 2009; Arya et al., 2011; Chen et al., 2011; Laxmi et al., 2011). Concurrently, a diverse range of *in vitro* and *in vivo* test systems has been used to evaluate the pharmacological properties of *S. chirayita*. Evidence-based laboratory investigations indicate that aqueous, alcoholic and methanolic extracts of *S. chirayita* possess a number of promising pharmacological properties. The whole plant of *S. chirayita* have been reported to be used for the treatment of antibacterial and antifungal activity (Alam et al., 2009; Laxmi et al., 2011; Rehman et al., 2011). Anti-hepatitis B virus activity of *S. chirayita* extracts was also studied on HepG 2.2.15 cells line (Zhou et al., 2015). The whole plant of *S. chirayita* has been reported for the anti-inflammatory and hypoglycemic activity (Banerjee et al., 2000; Kar et al., 2003; Alam et al., 2011; Das et al., 2012; Verma et al., 2013). Chen et al. (2011) investigated the 70% ethanolic extract of *S. chirayita* for antioxidant activities by using antioxidant tests including reducing power and beta-carotene assay. The results showed that 70% ethanolic extracts exhibited high DPPH scavenging activity (IC<sub>50</sub> = 267.80 µg/mL). Table 2 presents a summary focusing on the pharmacological evaluations using *in vitro* and *in vivo* systems whereas Table 3 provides antioxidant potential of *S. chirayita*.

**PHYTOCHEMISTRY**

The widespread uses of *S. chirayita* as a traditional drug and its commercialization in modern medical systems have led to a rise in scientific exploration of its phytochemistry in order to identify
| Bioactivity evaluated | Plant part(s) tested | Test system | Test Organism/Models | Control | Toxicity test | References |
|-----------------------|----------------------|-------------|----------------------|---------|--------------|------------|
| Antibacterial         | Whole plant          | in vitro    | EtOH                 | Escherichia coli ATCC 26922 | Ciprofloxacin | None | Rehman et al., 2011 |
|                       |                      |             |                      | Klebsiella pneumonia ATCC 15380 |              |      |                        |
|                       |                      |             |                      | Pseudomonas aeruginosa ATCC 25619 |              |      |                        |
|                       |                      |             |                      | Proteus vulgaris ATCC 6380 |              |      |                        |
|                       | Stem                 | in vitro    | MeOH                 | Bacillus subtilis ATCC 8633 | Ceftriaxone, Ceftriaxone sodium, Cefuroxine, Ciprofloxacin, Gentamycine, Levofloxacin, Metronidazole, Tranexamic acid | None | Khalid et al., 2011 |
|                       |                      |             |                      | Enterococcus faecalis (ATCC 14506) |              |      |                        |
|                       |                      |             |                      | Staphylococcus aureus (ATCC 6538) |              |      |                        |
|                       |                      |             |                      | Pseudomonas aeruginosa (ATCC 27853) |              |      |                        |
|                       |                      |             |                      | Salmonella typhi (ATCC 14028) |              |      |                        |
|                       | Whole plant          | in vitro    | MeOH                 | Bacillus subtilis MTCC 736 | Gentamycin | None | Laxmi et al., 2011 |
|                       |                      |             |                      | Bacillus polymyxa |              |      |                        |
|                       |                      |             |                      | Staphylococcus aureus MTCC 3160 |              |      |                        |
|                       |                      |             |                      | Escherichia coli MTCC 723 |              |      |                        |
|                       |                      |             |                      | Salmonella typhi MTCC 3216 |              |      |                        |
|                       |                      |             |                      | Vibrio cholera MTCC 3906 |              |      |                        |
|                       |                      |             |                      | Streptococcus pyogenes MTCC 1927 |              |      |                        |
|                       |                      |             |                      | Proteus mirabilis MTCC 1429 |              |      |                        |
|                       |                      |             |                      | Providencia alcalifaciens |              |      |                        |
|                       |                      |             |                      | Pseudomonas aeruginosa MTCC 7837 |              |      |                        |
|                       | Whole plant          | in vitro    | DCM; EtOH            | Staphylococcus aureus | Kanamycin 30 µg/disc | None | Alam et al., 2009 |
|                       | Stem                 | in vitro    | EtOH                 | Staphylococcus aureus | Chloramphenicol 30 µg/disc | Brine shrimp assay–positive | Sultana et al., 2007 |
|                       |                      |             |                      | Bacillus subtillis |              |      |                        |
|                       |                      |             |                      | Salmonella typhi |              |      |                        |
|                       |                      |             |                      | Shigella flexneriae |              |      |                        |
|                       |                      |             |                      | Sarcina lutea |              |      |                        |
|                       |                      |             |                      | Bacillus megaterium |              |      |                        |
| Antifungal            | Whole plant          | in vitro    | MeOH                 | Aspergillus niger MTCC 1881 | Amphotericin | None | Laxmi et al., 2011 |
|                       |                      |             |                      | Aspergillus flavus MTCC 1883 |              |      |                        |
|                       |                      |             |                      | Cladosporium oxysporum MTCC 1777 |              |      |                        |
| Antileishmanial       | Aerial part          | in vitro    | 95% EtOH             | Leishmania donovani UP6 | – | None | Ray et al., 1996 |
| Antileishmanial       | Whole plant          | in vitro    | MeOH                 | Leishmania donovani AG83 | – | Cytotoxicity test-negative | Medda et al., 1999 |
| Antihelmintic         | Whole plant          | in vitro    | Water; MeOH          | Haemonchus contortus | Levamisole 0.55 mg/ml | None | Iqbal et al., 2006 |
| Antimalarial          | Leaves/Stem          | in vitro    | MeOH; PE; Water; EtOH| Plasmodium falciparum FCK 2 | Parasitized red blood cells and 10 µCi of [35S]-methionine | None | Bhat and Surolia, 2001 |
TABLE 2 | Continued

| Bioactivity evaluated | Plant part(s) tested | Test system | #Extracting solvent | Test Organism/Models | Control | Toxicity test | References |
|-----------------------|----------------------|-------------|---------------------|----------------------|---------|--------------|------------|
| Egg hatchability and larvicidal | Whole plant | in vitro | HEX; EA; MeOH | Aedes aegypti | Tween-80 | None | Balaraju et al., 2009b |
| Anti-hepatitis B virus | Whole plant | in vitro | 50% EtOH | HepG 2.2.15 cells line | Tenofovir | None | Zhou et al., 2015 |
| Antinflammatory | Aerial parts | in vivo | Petroleum | N/A | Mice treated with vehicle or Diclofenac (10 mg/kg) | None | Banerjee et al., 2000 |
| Antinflammatory | Root | in vivo | 95% EtOH | N/A | Diclofenac (25 mg/kg) | None | Das et al., 2012 |
| Hypoglycemic | Whole plant | in vivo | 95% EtOH | N/A | Mice treated with vehicle | None | Kar et al., 2003 |
| Hypoglycemic | Leaves | in vivo | EtOH | N/A | Glibenclamide (5 mg/kg) | None | Alam et al., 2011 |
| Hypoglycemic | Whole plant | in vivo | EA; EtOH | N/A | Glibenclamide (5 mg/kg) | Cytotoxicity test-negative | Verma et al., 2013 |
| Antidiabetic | Whole plant | in vitro | 95% EtOH; HEX | STZ-NAD(streptozotocin-nicotinamide) induced diabetic albino mice | Metformin (100 µg/kg) | None | Grover et al., 2002 |
| Antidiabetic | Whole plant | in vitro | EtOH; HEX; Chloroform | STZ-NAD(streptozotocin-nicotinamide) induced diabetic albino mice | Metformin (100 µg/kg) | None | Arya et al., 2011 |
| Antipyretic | Root | in vitro | Water | Brewer’s yeast induced pyrexia Typhoid-Paratyphoid A, B vaccine induced Hyperexia | Paracetamol (150 mg kg⁻¹) | None | Bhargava et al., 2009 |
| Anticarcinogenic | Whole plant | in vivo | HEX | N/A | 9,10-dimethyl benzo(a)anthracene (DMBA) | None | Saha et al., 2004 |
| Analgesic | Leaves/Stem | in vivo | EtOH | N/A | Diclofenac sodium (25 mg/kg) | None | Alam et al., 2010 |
| Analgesic | Root | in vivo | EtOH | N/A | Aminopyrine (50 mg/kg) | None | Das et al., 2012 |
| Hepatoprotective | Aerial parts | in vivo | 70% EtOH | N/A | Paracetamol (150 mg/kg) | None | Nagalekshmi et al., 2011 |
| CNS | Whole plant | in vivo | EtOH | N/A | Mice treated with vehicle | None | Bhattacharya et al., 1976 |
| Antiviral | Leaves/Stem | in vitro | Water | Herpes simplex virus type-1 | Acyclovir (1 mg/mL) | Cytotoxicity test-negative | Verma et al., 2008 |

#Extracting solvent: EtOH, ethanol; EA, ethyl acetate; HEX, hexane; MeOH, methanol; N/A, not applicable; PE, petroleum ether.

the active phytochemicals. This has resulted in a considerable body of literature exploring the chemical constituents of this plant (Mandal and Chatterjee, 1987; Chakravarty et al., 1991, 1994; Mandal et al., 1992; Chatterjee and Pakrashi, 1995; Pant et al., 2000). The wide-range biological activities of *S. chirayita* are attributed to the presence of a diverse group of pharmacologically bioactive compounds belonging to different classes such as xanthones and their derivatives, lignans, alkaloids, flavonoids, terpenoids, iridoids, secoiridoids, and other compounds such as chiratin, ophelicacid, palmitic acid, oleic acid, and stearic acid (Pant et al., 2000; Patil et al., 2013). The first isolated dimeric xanthone was chiratanin present in different parts of *S. chirayita*. The pharmacological efficacy of *S. chirayita* has been partly attributed to the biological activity of major phytoconstituents including amarogentin, swertiamarin, mangiferin, swerchirin, sweroside, amaroswerin,
TABLE 3 | Antioxidant potential of different solvent extracts of S. chirayita

| Plant part tested | #Extracting solvent | Test system | Control used and result | Toxicity test | References |
|-------------------|---------------------|-------------|-------------------------|---------------|------------|
| Whole plant       | 70% EtOH            | In vitro    | BHT and Vitamin C       | None          | Chen et al., 2011 |
|                   |                     |             | IC$_{50}$ = 267.80 µg/mL (DPPH) |               |            |
|                   |                     |             | IC$_{50}$ = 1.502 ± 0.200 µg/mL (β-carotene) |               |            |
|                   |                     |             | IC$_{50}$ = 6.50 µg/mL (ABTS) |               |            |
| Whole plant       | 70% EtOH            | In vivo     | NA                      | Cytotoxicity test-negative | Chen et al., 2011 |
| Whole plant       | MeOH                | In vitro    | BHT                     | None          | Sharma et al., 2013b |
| Whole plant       | MeOH                | In vitro    | BHA                     | None          | Ahirwal et al., 2014 |
| Whole plant       | Water               | In vitro    | Gallic acid             | None          | Kumar et al., 2013 |
| Leaves            | Water               | In vitro    | BHA; BHT                | None          | Ghosh et al., 2013 |
|                   |                     |             | IC$_{50}$ = 86 µg/mL (DPPH) |               |            |
|                   |                     |             | 900 ± 11 (4 min) and 2070 ± 110 (30 min) µM Fe (II)/g sample DW (FRAP) |               |            |
| Whole plant       | 12% EtOH            | In vitro    | Ascorbic acid           | None          | Phoboo et al., 2013 |
| Whole plant       | MeOH                | In vitro    | Gallic acid             | None          | Kshirsagar et al., 2015 |

ABTS, 2,2-azino-bis (3-ethylbenzthiazoline-6-sulfonicacid); BHA, Butylated hydroxy anisole; BHT, Butylated hydroxytoluene; DPPH, 2,2-Diphenyl-1-picrylhydrazyl; DW, Dry weight; FRAP, Ferric Reducing Antioxidant Power

and gentiopicrin (Figure 3). Amarogentin is reported to be anti-diabetic (Phoboo et al., 2013), anticancerous (Saha et al., 2006; Pal et al., 2012), and antileishmanial (Ray et al., 1996; Medda et al., 1999), whereas swertiamarin has been tested for its anti-hepatitis (Wang et al., 2001), anticanical (Kavimani and Manisenthilkumar, 2000), anti-arthritis activities (Saravanan et al., 2014). It has been shown to exhibit anti-diabetic (Vaidya et al., 2013) properties. Mangiferin is also reported to have anti-diabetic, antiatherosclerotic (Pardo-Andreu et al., 2008), anticanical, antihIV (Guha et al., 1996), antiparkinson (Kavitha et al., 2013), and chemopreventive (Yoshimi et al., 2001) activities. Swerchirin is known to be antimalarial, hypoglycemic (Bajpai et al., 1991; Saxena et al., 1996), hepatoprotective, pro-heamatopoietic (Ya et al., 1999), with blood glucose lowering activity (Sekar et al., 1987; Saxena et al., 1991) and weak chemo preventive pharmacological effects (Hirakawa et al., 2005). Swerchirin at different concentrations (1, 10, and 100 µM) significantly enhanced glucose stimulated insulin release from isolated islets (Saxena et al., 1993). Swerchirin is reported to be antibacterial (Siler et al., 2010), hepatoprotective (Liu et al., 1994; Luo et al., 2009), preventative in treatment for hyperpigmentation (Jeong et al., 2015), and is also suggested as a promising osteoporosis

therapeutic natural product (Sun et al., 2013). Amaroswerin is known for its gastroprotective effects of the bitter principles (Niiho et al., 2006). Table 4 provides a summary focusing on the biological activity of the phytochemicals present in S. chirayita.

SAFETY EVALUATION

Concerns regarding safety of conventional drugs are vital issues of pharmaceutical industries. Studies have indicated that some commonly used medicinal plants may be mutagenic or cytotoxic especially over a long period of use (Verschaeve and Van Staden, 2008). There is increasing evidence on the toxicity of crude extracts and isolated compounds from different plant species (Koorbanally et al., 2006). However, despite its long history of use in traditional medicine, there is still a lack of scientific information concerning the safety evaluation of S. chirayita. It can be traced through the medicinal history as a nontoxic and safe ethnomedical herb and has been mentioned in medical papyri to expel fever, relieve headache, inflammation, and to stimulate the central nervous system. S. chirayita extracts, did not cause obvious toxic effects in mice as there were no significant differences in body weight and body temperature between the

Frontiers in Pharmacology | www.frontiersin.org
January 2016 | Volume 6 | Article 308

7
treated and control groups (Alam et al., 2011; Das et al., 2012). A clinical study by Medda et al. (1999) concluded that *S. chirayita* revealed no evidence of toxicity in both liposomal and niosomal forms. Furthermore, stringent efforts are required to further delineate the well-documented toxicological properties involving toxicity and mutagenic tests to evaluate the safety of this plant. Nevertheless, rigorous clinical studies involving different mechanisms are still needed to confirm the safety of *S. chirayita* in traditional medicine so that it can be used safely and effectively. Despite the fact that the benefits of medicinal plants is globally acknowledged, the need for better insight on the safety evaluation remains essential, so as to differentiate between toxic effects and pharmacological importance of plant extracts (Aremu and Van Staden, 2013).

**SWERTIA CHIRAYITA CONSERVATION**

Destruction of plant resources is a normal occurrence. The current speed of extinction through human interferences is estimated to be approximately 100–1000 times faster than the natural speed of extinction (Chapin et al., 2000). Due to developmental activities in the Himalayan region, wild populations of many medicinal plants, including *S. chirayita* are reduced to the verge of extinction. *S. chirayita* is traded and used mostly as a traditional drug. Due to its multiple uses the demand is on the rise by both national and international trading leading to increasing over harvesting of wild populations. This has resulted in drastic reductions of its populations. Lack of comprehensive data on annual harvested and traded plants of *S. chirayita* is also a major concern. According to the International Union of Conservation of Nature (IUCN) criteria, *S. chirayita* conservation status has been categorized as “critically endangered” (Joshi and Dhawan, 2005). *S. chirayita* is among the 32 most highly prioritized medicinal plants of India as identified by The National Medicinal Plant Board, Government of India (http://www.nmpb.nic.in).

The implication of losing this plant species due to extinction lies not only in the loss of genes useful for plant development or in the biosynthesis of new compounds but also the loss of potentially novel compounds of pharmaceutical or nutraceutical benefit. In order to meet the escalating demand in national and international trade markets of raw plants, cultivation must be escalated. There are limitations in the use of seed propagation, due to low viability, and low germination percentages (Badola and Pal, 2002; Chandra et al., 2012). Biotechnology offers new means of improving biodiversity and biotechnological approaches such as micropropagation techniques (Figure 1E) has received more attention and may play a vital role in the establishment of genetically uniform plants for the *Swertia* industry. It is believed that the development of efficient micropropagation protocols, can guarantee an adequate supply of *S. chirayita* plants (devoid of environmental-imposed constraints) with subsequent reduction in uncontrolled harvesting pressure on wild populations. Several studies reported on micropropagation, somatic embryogenesis and acclimatization procedures with the capacity to produce many uniform *S. chirayita* clones throughout...
TABLE 4 | Important bioactive compounds isolated from Swertia chirayita.

| Phytochemical | Biological activity | References |
|---------------|---------------------|------------|
| Amarogentin   | Antileishmanial     | Ray et al., 1996; Medda et al., 1999 |
| Topoisomerase inhibitor |         | Ray et al., 1996 |
| Anticancer    |                     | Saha et al., 2006; Pal et al., 2012 |
| Anti-diabetic | Gastroprotective    | Phoboo et al., 2013; Niho et al., 2006 |
| Swertiamarin  | CNS depressant      | Bhattacharya et al., 1976 |
| Anticholinergic |                   | Suparna et al., 1998 |
| Anticancer    |                     | Kavirani and Manisenthikumar, 2000 |
| Anti-hepatitis |                     | Wang et al., 2001 |
| Antibacterial |                     | Kumarasamy et al., 2003 |
| Cardio-protective, anti-atherosclerotic |         | Vaidya et al., 2009 |
| anti-diabetic |                     | Vaidya et al., 2013 |
| Anti-arthritis |                   | Saravanan et al., 2014 |
| Mangiferin    | Antiviral           | Zheng and Lu, 1990 |
| Immunomodulatory, antitumor, anti-HIV |     | Guha et al., 1996 |
| Antioxidant   |                     | Sanchez et al., 2000 |
| Chemopreventive |                   | Yoshimi et al., 2001 |
| Antiinflammatory |                 | Kumar et al., 2003 |
| Hypoglycemic  |                     | Murugananadan et al., 2005 |
| Anti-diabetic, Antiatherosclerotic |         | Pardo-Andreu et al., 2008 |
| Antiparkinson |                   | Kavitha et al., 2013 |
| Swerchirin    | Hypoglycemic        | Bajpai et al., 1991; Saxena et al., 1996 |
| Hepatoprotective, pro-heamatopoietic |     | Ya et al., 1999 |
| Blood glucose lowering activity |         | Sekar et al., 1987; Saxena et al., 1993 |
| Chemopreventive |                   | Hirakawa et al., 2005 |
| Sweroside     | Antibacterial       | Siler et al., 2010 |
| Hepatoprotective |                 | Liu et al., 1994; Luo et al., 2009 |
| Hyperpigmentation |                | Jeong et al., 2015 |
| Osteopigmentation |               | Sun et al., 2013 |
| Amaroswerin   | Gastroprotective    | Niho et al., 2006 |
| Gentianine    | Antipsychotic      | Bhattacharya et al., 1974 |
| Antimalarial  |                     | Natarajan et al., 1974 |
| Oleanolic acid | Antimicrobial      | Jesus et al., 2015 |
| Antitumor     |                     | Soica et al., 2014 |
| Antilinflammatory, antioxidant |         | Liu, 1995 |
| Ursolic acid  | Antimicrobial       | Jesus et al., 2015 |

(Continued)

TABLE 4 | Continued

| Phytochemical | Biological activity | References |
|---------------|---------------------|------------|
| Antitumor     |                     | Bonaccorsi et al., 2008; Soica et al., 2014 |
| Swertanone    | Antinflammatory     | Kumar et al., 2003; Tabassum et al., 2012 |
| Syringaresinol | Hepatoprotective   | Chakravarty et al., 1994 |
| Bellidifolin  | Hypoglycemic        | Basnet et al., 1995 |
| Isobellidifolin |                 | Basnet et al., 1995 |
| 1-Hydroxy-3,5,8-trimethoxyxanthone | Antimalarial | Mandal and Chatterjee, 1994 |
| 1-Hydroxy-3,7,8-trimethoxyxanthone | Spasmogenic agent | Ateufack et al., 2007 |
| β-Amyrin      | Anti-inflammatory   | Holanda et al., 2008 |
| Chiratol      | Anti-inflammatory, antifungal | Vázquez et al., 2012 |

the year (Kumar and Chandra, 2013, 2014; Kumar et al., 2014). As shown in Table 5, micropropagation protocols have successfully been established for S. chirayita using different explants.

Synthetic seed technology is also an applied application of modern plant biotechnology which offers tremendous potential for easy handling, micropropagation and plant germplasm conservation through cryopreservation (Ara et al., 2000; Sharma et al., 2013a; Perveen and Anis, 2014; Gantait et al., 2015). Successful implementation of synthetic seed technology for mass propagation and short-term storage of genetically uniform clones require manipulation of in vitro tissue culture systems that are able to transform into complete plantlets (Ara et al., 2000). Recently, Kumar et al. (2014) reported on synthetic seed production and plant regeneration of S. chirayita from somatic embryos. However, further studies are required to improve technology so that it can be used on a commercial scale.

Many plant secondary metabolites accumulate in roots (Flores et al., 1999) but harvesting of these organs is destructive. Therefore, in the recent past Agrobacterium rhizogenes induced hairy root technology has received attention and engaged a new platform of applied research in generating pharmaceutical lead compounds. The large scaling-up of hairy root cultures is of importance for biotechnological applications (Guillon et al., 2006). Attempts have been made to standardize A. rhizogenes transformed root cultures for production of active secondary metabolites under in vitro conditions of S. chirayita (Keil et al., 2000). For commercialization of S. chirayita adventitious roots and to elucidate the feasibility
for commercial application, hairy root technology is required along with various factors affecting the production of root biomass and bioactive compounds. Overall, micropropagation which is conducted under a controlled environment will help to prevent the current plant biodiversity conservation problems arising from over harvesting practices of wild populations and can profoundly improve the quality of bioactive secondary metabolites of this age old medicinal plant *S. chirayita*.

**CONCLUSIONS AND FUTURE PERSPECTIVES**

*S. chirayita* offers many promising prospects for both traditional and modern medicine. *S. chirayita* is apparently a potential herbal therapy for many ailments. This review summarized the existing ethnobotanical uses, phytochemistry, pharmacological activities, safety evaluation, and conservation status on *S. chirayita*.

So far no serious side effects or toxicity of *S. chirayita* have been reported, but further toxicological studies are still needed to confirm the safety of *S. chirayita* in humans. Efforts are required for further studies, especially evaluating its biological activities *in vivo* and toxicological and mutagenic properties in order to better validate the safety of these different plant derives compounds. In all probability there is a need for clinical trials to establish the efficacy of using *S. chirayita* in medicine. Due to its multiple uses the demand in both national and international markets is constantly on the rise. Overexploitation combined with habitat destruction has resulted in the drastic reduction of its population. For the successful commercialization of this critically endangered medicinal plant any proposed research must be viewed in a wider context that includes conservation practices and sustainable supply of raw plants. This will require innovative tools, which utilize biotechnological interventions, including micropropagation, cryopreservation, and bioreactors for the conservation, as well as for raising commercial production. In synthetic seed technology more detailed research is required mainly for improvement in germination frequency of synthetic seeds and subsequent plantlet growth in soil so that it can be used on a commercial scale. Additionally, in the near future, hairy root technology can be used as a model system and will also provide plant biotechnologists with powerful tools to improve the valuable phytochemicals of *S. chirayita*. Although efficient micropropagation protocols have been established,
further studies focusing on seed biology and ways of improving bioactive secondary metabolites in cultivated *S. chirayita* would be beneficial for their commercialization. Quality control protocols to prevent misidentification and possible adulteration of *S. chirayita* are also needed. In summary, *S. chirayita* have been studied extensively in terms of taxonomy, ethnobotany, phytochemistry, biological activities, and conservation. However, new findings may increase the present therapeutic importance of *S. chirayita* and promote their future use in modern medicine, while novel biotechnological approaches are required for further conservation.

**REFERENCES**

Ahirwal, L., Singh, S., Dubey, M. K., Bharti, V., and Mehta, A. (2014). Investigation of antioxidant potential of methanolic extract of *Swertia chirita* Buch. *Ham. Eur. J. Med. Plants*. 4, 1345–1355. doi: 10.9734/EJMP/2014/8933

Ahuja, A., Koul, S., Kaul, B. L., Verma, N. K., Kaul, M. K., Raina, R. K., et al. (2003). *Media Composition for Faster Propagation of Swertia chirita*. US Patent No. WO/03/045132 A1.

Alam, K. D., Ali, M. S., Mahjabeen, S., Hassan, M. R., Rahman, M. F., and Ahamed, R. (2009). Antidiabetic effect of whole plant fraction of *Swertia chirayita*-An Indian subcontinent herb with important medicinal value. *Pharmacologyonline* 2, 642–647.

Alam, K. D., Ali, M. S., Mahjabeen, S., Parvin, S., Akbar, M. A., and Ahamed, R. (2010). Report: analgesic activities of ethanol extract of leaf, stem and their different fractions of *Swertia chirita*. *Pak. J. Pharm. Sci.* 23, 455–457.

Ali, M. S., Mahjabeen, S., Parvin, S., Akbar, M. A., and Ahamed, R. (2009). In vitro antimicrobial activities of different fractions of *Swertia chirata* ethanolic extract. *Pak. J. Biol. Sci.* 12, 1334–1337. doi: 10.3923/pjbs.2009.1334.1337

Anon (1982). *In The Wealth of India: Raw Materials, Publication and Information Directorate, Vol X*: New Delhi: CSIR, 78–81.

Ara, H., Jaiswal, U., and Jaiswal, V. S. (2000). Synthetic seed: prospects and limitations. *Curr. Sci.* 78, 1438–1444.

Areumu, A. O., and Van Staden, J. (2013). The genus *Alam*, K. D., Ali, M. S., Mahjabeen, S., Parvin, S., Akbar, M. A., and Ahamed, R. (2009). Antidiabetic effect of whole plant fraction of *Swertia chirayita*-An Indian subcontinent herb with important medicinal value. *Pharmacologyonline* 2, 642–647.

Ahamed, R. (2009). *Swertia chirata* — An endangered medicinal herb via direct somatic embryogenesis. *Acta Physiol. Plant.* 33, 1123–1133. doi: 10.1007/s11738-010-0640-5

Balaraju, K., Agastian, P., and Ignacimuthu, S. (2009a). Micropropagation of *Swertia chirata*—A critically endangered medicinal herb. *Phytochemistry* 30, 4087–4092. doi: 10.1016/0031-1820(94)00018-7

Badola, H. K., and Pal, M. (2002). Endangered medicinal plant species in Himachal Pradesh. *Curr. Sci.* 83, 797–798.

Bajpai, M. B., Asthana, R. K., Sharma, N. K., Chatterjee, S. K., and Mukherjee, S. K. (1991). Hypoglycemic effect of swertiamarin from the methanol extract of the stem bark of *Ancholeistea vogelii* planch (loganiaceae) in rats. *Pharmacologyonline* 3, 374–384.

Bhat, G. P., and Surolia, N. (1976). Chemical constituents of Gentianaceae. XIX. CNS-depressant effects of swertianin. *Indian J. Chem. B* 304–308.

Bhat, A. J., Kumar, M., Negi, A. K., and Todaria, N. P. (2013). Informants’ consensus on ethnomedicinal plants in Kedarnath Wildlife Sanctuary of Indian Himalayas. *J. Med. Plants Res.* 7, 148–154.

Bhat, G. P., and Surolia, N. (2001). *In vitro* antimarial activity of extracts of three plants used in the traditional medicine of India. *Am. J. Trop. Med. Hyg.* 65, 304–308.

Bhat, A., Rawal, R. S., and Dhar, U. (2006). Ecological features of a critically rare medicinal plant, *Swertia chirayita*, in HIMALAYA. *Plant Species Biol.* 21, 49–52. doi: 10.1111/j.1442-1984.2006.00150.x

Bhattacharyya, S. K., Ghosal, S, Chaudhuri, R. K., Singh, A. K., and Sharma, P. V. (1974). “Letter: chemical constituents of gentianaceae. XI antipsychotic activity of gentianin.” *J. Pharm. Sci.* 63, 1341–1342. doi: 10.1002/jps.2600630850

Bhattacharyya, S. K., Reddy, P. K., Ghosal, S, Singh, A. K., and Sharma, P. V. (1976). *Chemical constituents of Gentianaceae*. XIX. CNS-depressant effects of swertiamarin. *Indian J. Pharm. Sci.* 65, 1547–1549. doi: 10.1026/2006.651037

Bonaccorsi, I., Altieri, F., Sciamanna, I., Oricchio, E., Grillo, C., Contartese, G., et al. (2008). Endogenous reverse transcriptase as a mediator of uracil acid’s antiproliferative and differentiating effects in human cancer cell lines. *Anticancer Res.* 28, 3113–3119. doi: 10.2187/ijc.2008-1352

Chakravarty, A. K., Mukhopadhyay, S., and Das, B. (1991). Swertian triterpenoids from *Swertia chirata*. *Phytochemistry* 30, 4087–4092. doi: 10.1016/0031-1820(94)00018-7

Chakravarty, A. K., Mukhopadhyay, S., and Das, B. (1994). *Swertia chirata*. *Indian J. Chem. B* 33, 405–408.

Chandra, S., Kumar, V., Bandopadhyay, R., and Sharma, M. M. (2012). SEM and elemental studies of *Swertia chirayita*: a critically endangered medicinal herb of temperate Himalayas. *Curr. Trends. Biotechnol. Pharm.* 6, 381–388.

Chaplin, F. S. III, Zavala, E. S., Eiven, V. T., Naylor, R. L., Vitousek, P. M., Reynolds, H. L., et al. (2000). Consequences of changing biodiversity. *Nature* 405, 234–242. doi: 10.1038/35012241

**AUTHOR CONTRIBUTIONS**

VK conducted the research and wrote the paper. JVS supervised the work and proof read the paper.

**ACKNOWLEDGMENTS**

VK is grateful to the National Research Foundation and the University of KwaZulu-Natal, South Africa for the financial support. Dr. M. Moyo and Dr. A. O. Areumu are thanked for reading the manuscript.
Kumar, V., Singh, S. K., Bandopadhyay, R., Sharma, M. M., and Chandra, S. (2014). *In vitro* organogenesis secondary metabolic production and heavy metal analysis in *Swertia chirayita*. *Cent. Eur. J. Biol.* 9, 686–698. doi: 10.2478/s11535-014-0300-7

Kumarasamy, Y., Nahar, L., Cox, P. J., Jaspars, M., and Sarker, S. D. (2003). Bioactivity of secoiridoid glycosides from *Centaurium erythraea*. *Phytochemistry* 50, 344–347. doi: 10.1016/S0031-9422(99)004857

Laxmi, A., Siddhartha, S., and Archana, M. (2011). Antimicrobial screening of methanol and aqueous extracts of *Swertia chirata*. *Int. J. Pharm. Pharm. Sci.* 3, 142–146.

Liu, J. (1995). Pharmacology of oleandrin acid and ursolic acid. *J. Ethnopharmacol.* 49, 57–68. doi: 10.1016/0378-8741(95)90032-2

Liu, J., Liu, Y. P., and Klassend, C. D. (1994). The effect of Chinese hepatoprotective medicines on experimental liver injury in mice. *J. Ethnopharmacol.* 42, 183–191. doi: 10.1016/0378-8741(94)90084-1

Luo, Y. D., Chen, J., Cao, J., Wen, X. D., and Li, P. (2009). Determination of sweroside in rat plasma and bile for oral bioavailability and hepatobiliary excretion. *Chem. Pharm. Bull.* 57, 79–83. doi: 10.1248/cpb.57.79

Malla, B., Gauchan, D. P., and Chhetri, R. B. (2015). An ethnobotanical study of medicinal plants used by ethnic people in Parbat district of western Nepal. *J. Ethnopharmacol.* 165, 103–117. doi: 10.1016/j.jep.2014.12.057

Mandal, S., and Chatterjee, A. (1994). Structure of chitinase, a novel dimeric xanthone. *Tetrahedron Lett.* 28, 1309–1310. doi: 10.1016/S0040-4039(08)7995-3

Mandal, S., and Chatterjee, A. (1994). *Seminar on Research in Ayurveda and Siddha*. New Delhi: CCRAS. 58–59.

Mandal, S., Das, P. C., and Joshi, P. C. (1992). Anti-inflammatory action of *Swertia chirata*. *Fitoterapia* 63, 122–128.

Medda, S., Mukhopadhyay, S., and Basu, M. K. (1999). Evaluation of the *Mangifera indica* L. extract (Vimang ™) for oral bioavailability and hepatobiliary overview. *Res. J. Pharmacogn. Phytochem.* 4, 187–194.

Saha, P., Mandal, S., Das, A., Das, P. C., and Das, S. (2004). Evaluation of the antiangiogenic activity of *Swertia chirata* Buch. Hamburg an Indian medicinal plant on DMBA-induced mouse skin carcinogenesis model. *Phytother. Res.* 18, 373–378. doi: 10.1002/ptr.1436

Saha, P., Mandal, S., Das, A., Das, S. (2006). Amarogentin can reduce hyperproliferation by downregulation of Cox-II upregulation of apoptosis in mouse skin carcinogenesis model. *Cancer Lett.* 244, 252–259. doi: 10.1016/j.canlet.2005.12.036

Sanchez, G. M., Re, L., Gillani, A., Nunez-Selles, A. J., Davison, G. P., and Leon-Fernandez, O. S. (2000). Protective effects of *Mangifera indica* L. extract, magiferin and selected antioxidant against TPA-induced biomolecules oxidation and peritoneal macrophage activation in mice. *Pharm. Res.* 42, 565–573. doi: 10.1007/phrs.2000.0727

Saravanan, S., Hairul Islam, V. I., Prakash Babu, N., Pandikumar, P., Thirugnanasambantham, K., Chellappanndian, M., et al. (2014). Svertiamarin attenuates inflammation mediators via modulating NF-κB/l I kB and JAK2/STAT3 transcription factors in adjuvant induced arthritis. *Eur. J. Pharm. Sci.* 56, 70–86. doi: 10.1016/j.ejps.2014.02.005

Saxena, A. M., Bajpai, M. B., and Mukherjee, S. K. (1991). Sverchirin induced attenuation of inflammation mediators via modulating NF-κB/ I kB and JAK2/STAT3 transcription factors in adjuvant induced arthritis. *Eur. J. Pharm. Sci.* 56, 70–86. doi: 10.1016/j.ejps.2014.02.005

Saxena, A. M., Bajpai, M. B., Murthy, P. S., and Mukherjee, S. K. (1993). Mechanism of blood sugar lowering by a Sverchirin-containing hexane fraction (SWI) of *Swertia chirayita*. *Indian J. Exp. Biol.* 31, 178–181.

Saxena, A. M., Murthy, P. S., and Mukherjee, S. K. (1996). Mode of action of three structurally different hypoglycemic agents: a comparative study. *Indian J. Exp. Biol.* 34, 351–355.

Scarlettini, P., and Speroni, E. (2000). Review on some plants of Indian traditional medicine with antioxidant activity. *J. Ethnopharmacol.* 71, 23–42. doi: 10.1016/S0378-8741(00)00213-0

Schimper, O., and Mauthner, H. (1996). Polyomethoxylated xanthones from the herb of *Centaurium erythraea* with strong antimutagenic properties in *Salmonella typhimurium*. *Planta Med.* 62, 561–564. doi: 10.1055/s-2006-957973

Sekar, B. C., Mukherjee, B., Chakravarti, R. B., and Mukherjee, S. K. (1987). Effect of different fractions of *Swertia chirayita* on the blood sugar level of albino rats. *J. Ethnopharmacol.* 21, 175–181. doi: 10.1016/0378-8741(87)90127-9

Shah, G. M., Abbasi, A. M., Khan, N., Guo, X., Khan, M. A., Hussain, M., et al. (2014). Traditional uses of medicinal plants against malarial disease by the tribal communities of Lesser Himalayas–Pakistan. *J. Ethnopharmacol.* 155, 450–462. doi: 10.1016/j.jep.2014.05.047

Sharma, N., Varshney, V. K., Kala, R. P., Bisht, B., and Sharma, M. (2013a). Antioxidant capacity and total phenolic content of *Swertia chirayita* (Roxb. ex Fleming) H. Karst. in Uttarakhand. *Int. J. Pharm. Sci. Res.* 23, 259–261.
Sharma, S., Shahzad, A., and Teixeira da Silva, J. A. (2013b). In vitro growth of Swertia chirayita Roxb. Ex Fleming co-cultured with plant growth promoting rhizobacteria. Plant Cell Tiss. Org. Cult. 121, 215–225. doi: 10.1007/s11240-014-0696-9

Siler, B., Misić, D., Nestorović, J., Banjanac, T., Glamoclija, J., Soković, M., et al. (2010). Antibacterial and antifungal screening of Centaurea pulchellum crude extracts and main secoiridoid compounds. Nat. Prod. Commun. 5, 1525–1530.

Soica, C., Oporean, C., Borcan, F., Danciu, C., Trandafirescu, C., Coricovac, D., et al. (2014). The Synergistic biologic activity of oleanolic and ursolic acids in complex with Hydroxypropyl-α-Cyclodextrin. Molecules 19, 4924–4940. doi: 10.3390/molecules19044924

Sultana, M. J., Molla, M. T. H., Alam, M. T., and Ahmed, F. R. S. (2007). Investigation of antimicrobial activities of the plant Swertia chirayita ham. J. Life Earth Sci. 2, 31–34.

Sun, H., Li, L., Zhang, A., Zhang, N., Lv, H., Sun, W., et al. (2013). Protective effects of sweroside on human MG-63 cells and rat osteoblasts. Fitoterapia 84, 174–179. doi: 10.1016/j.fitote.2012.11.010

Suparna, M., Ranjana, J., and Sibabratra, M. (1998). Naturally occurring with pharmacological activity. Indian J. Pharm. Sci. 60, 123–127.

Tabassum, S., Mahmood, S., Hanif, J., Hina, M., and Uzair, B. (2012). An overview of medicinal importance of Swertia chirayita. Int. J. Appl. Sci. Tec. 2, 298–304.

Vaidya, H., Goyal, R. K., and Cheema, S. K. (2013). Anti-diabetic activity of swertiamarin is due to an active metabolite, gentianine, that upregulates PPAR-γ gene expression in 3T3-L1 cells. Phytother. Res. 27, 624–627. doi: 10.1002/ptr.4763

Vaidya, H., Rajani, M., Sudarshan, V., Padh, H., and Goyal, R. (2009). Swertiamarin: a lead from Eucosopetra littoralis for anti-hyperlipidaemic effect. Eur. J. Pharm. Biopharm. 67, 108–112. doi: 10.1016/j.ejpb.2009.06.053

Vázquez, L. H., Palazon, J., and Navarro-Ocaña, A. (2012). “The pentacyclic triterpenes α, β-amyrins: a review of sources and biological activities,” in Phytochemicals—A Global Perspective of Their Role in Nutrition and Health, ed Venkateshwar Rao (In Tech), 487–502.

Verma, H., Patil, P. R., Kolhapure, R. M., and Gopalkrishna, V. (2008). Antiviral activity of the Indian medicinal plant extract, Swertia chirata against herpes simplex viruses: a study by in-vitro and molecular approach. Indian J. Med. Microbiol. 26, 322–326. doi: 10.4103/0255-0857.43561

Verma, V. K., Sarwa, K. K., Kumar, A., and Zaman, M. K. (2013). Comparison of hepatoprotective activity of Swertia chirayita and Andrographis paniculata plant of North East India against CCl4 induced hepatotoxic rats. J. Pharm. Res. 7, 647–653. doi: 10.1016/j.jphr.2013.07.008

Vercelae, L., and Van Staden, J. (2008). Mutagenic and antimutagenic properties of extracts from South African traditional medicinal plants. J. Ethnopharmacol. 119, 575–587. doi: 10.1016/j.jep.2008.06.007

Wang, C. Z., Maier, U. H., Eisenreich, W., Adam, P., and Obersteiner, I. (2001). Unexpected biosynthetic precursors of amargorin a retrobiosynthetic 13C NMR study. Eur. J. Org. Chem. 2001, 1459–1465. doi: 10.1002/1099-0690(200104)2001:8<1459::AID-EJOC1459>3.0.CO;2-0

Wang, L., Lizhe, A., Yanping, H., Lixin, W., and Yi, L. (2009). Influence of phytocides and medium on the shoot regeneration from the leaf of Swertia chirayita Buch.-Ham. Ex. wall. in vitro. Afr. J. Biotechnol. 8, 2513–2517. doi: 10.4314/ajb.v8i11.60746

Wawrosch, C., Maskay, N., and Kopp, B. (1999). Micropropagation of the threatened Nepalese medicinal plant Swertia chirata Buch.-Ham.ex wall. Plant Cell Rep. 18, 997–1001. doi: 10.1007/s002990050697

Ya, B. Q., Nian, L. C., Li, C., and Gen, X. P. (1999). Protective effect of swerchirin on hematopoiesis in 60Co-irradiated mice. Phytomed. 6, 85–88. doi: 10.1016/S0924-7113(99)80040-3

Yoshimi, N., Matsunaga, K., Katayama, M., Yamada, Y., Kuno, T., Qiao, Z., et al. (2001). The inhibitory effects of mangiferin, a naturally occurring glucosylxanthone, in bowel carcinogenesis of male F344 rats. Cancer Lett. 163, 163–170. doi: 10.1016/S0304-3835(00)00678-9

Zheng, M. S., and Lu, Z. Y. (1990). Antiviral effect of mangiferin and iso-mangiferin on herpes simplex virus. Chinese Med. J. 103, 160–165.

Zhou, N. J., Geng, C. A., Huang, X. Y., Ma, Y. B., Zhang, X. M., Wang, J. L., et al. (2015). Anti-hepatitis B virus active constituents from Swertia chirayita. Fitoterapia 100, 27–34. doi: 10.1016/j.fitote.2014.11.011

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Kumar and Van Staden. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.